1. Search Result
Search Result
Results for "

Oral diseases

" in MedChemExpress (MCE) Product Catalog:

2504

Inhibitors & Agonists

2

Screening Libraries

5

Fluorescent Dyes

38

Biochemical Assay Reagents

28

Peptides

435

Natural
Products

205

Isotope-Labeled Compounds

13

Click Chemistry

12

Oligonucleotides

2

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-111372
    Finerenone
    5+ Cited Publications

    BAY 94-8862

    Mineralocorticoid Receptor Cardiovascular Disease Metabolic Disease
    Finerenone (BAY 94-8862) is a third-generation, selective, and orally active nonsteroidal mineralocorticoid receptor (MR) antagonist (IC50 = 18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (> 500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .
    Finerenone
  • HY-100411
    MLi-2
    10+ Cited Publications

    LRRK2 Neurological Disease
    MLi-2, a chemical probe, is an orally active and highly selective LRRK2 inhibitor with an IC50 of 0.76 nM. MLi-2 has the potential for Parkinson’s disease .
    MLi-2
  • HY-16743
    Ibiglustat
    3 Publications Verification

    Venglustat; SAR402671; GZ402671

    Glucosylceramide Synthase (GCS) Metabolic Disease
    Ibiglustat (Venglustat) is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease .
    Ibiglustat
  • HY-17020
    Miglustat
    5+ Cited Publications

    N-Butyldeoxynojirimycin; NB-DNJ; OGT 918

    Glucosylceramide Synthase (GCS) Neurological Disease Inflammation/Immunology
    Miglustat (N-Butyldeoxynojirimycin) is an orally active and reversible ceramide glucosyltransferase inhibitor. Miglustat can be used for the research of type I gaucher disease .
    Miglustat
  • HY-B0203A
    Nebivolol hydrochloride
    3 Publications Verification

    R 065824 hydrochloride

    Adrenergic Receptor Cardiovascular Disease Endocrinology Cancer
    Nebivolol (R 065824) hydrochloride is an orally active beta receptor blocker and has the high beta(1)-receptor affinity.Nebivolol hydrochloride has direct vasodilator properties and adrenergic blocking characteristics. Nebivolol hydrochloride can be used for the research of kinds of diseases such as hypertension, coronary artery disease, congestive heart failure and ischemic heart disease .
    Nebivolol hydrochloride
  • HY-P4153

    MK-0616 chloride

    PCSK9 Cardiovascular Disease
    Enlicitide chloride is an orally active inhibitor for PCSK9 that blocks the interaction between LPL receptor and PSCK9, with an IC50 of 2.5 nM. Enlicitide chloride can be used in the study of cardiovascular diseases such as atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome or related cardiovascular and cardiometabolic disorders .
    Enlicitide chloride
  • HY-111669
    Zervimesine
    1 Publications Verification

    CT1812; Sigma-2 receptor antagonist 1

    Sigma Receptor Neurological Disease
    Zervimesine (CT1812) is an orally active and brain penetrant sigma-2 receptor antagonist with a Ki of 8.5 nM. Zervimesine can be used for the research of Alzheimer’s disease .
    Zervimesine
  • HY-16759
    Verubecestat
    5 Publications Verification

    MK-8931

    Beta-secretase Neurological Disease
    Verubecestat (MK-8931) is an orally active, high-affinity BACE1 and BACE2 inhibitor with Ki values of 2.2 nM and 0.38 nM. Verubecestat effectively reduces Aβ40 and has the potential for Alzheimer's Disease .
    Verubecestat
  • HY-135825
    TFEB activator 1
    5+ Cited Publications

    Autophagy Neurological Disease
    TFEB activator 1 is an orally effective, mTOR-independent activator of TFEB. TFEB activator 1 significantly promotes the nuclear translocation of Flag-TFEB with an EC50 of 2167 nM. TFEB activator 1 enhances autophagy without inhibiting the mTOR pathway and has the potential for neurodegenerative diseases treatment .
    TFEB activator 1
  • HY-132831
    Selnoflast
    1 Publications Verification

    Somalix; RO-7486967; IZD334

    NOD-like Receptor (NLR) Interleukin Related Neurological Disease Inflammation/Immunology
    Selnoflast (RO7486967), formerly somalix/RG6418/IZD334, is an orally active, potent, selective and reversible small molecule NLRP3 inflammasome inhibitor. Selnoflast is a potent inhibitor of IL-1β release stimulated by NLRP3 activation in human Alzheimer's disease (AD) monocyte-derived macrophages. Selnoflast is promising for research of AD and systemic inflammatory diseases, such as ulcerative colitis and chronic obstructive pulmonary disease .
    Selnoflast
  • HY-134661A
    Solangepras
    1 Publications Verification

    CVN424

    GPR6 Neurological Disease
    CVN424 is an orally active and selective GPR6 inverse agonist with a Ki of 9.4 nM and an EC50 of 38 nM. CVN424 is brain-penetrant and has the potential for Parkinson disease research .
    Solangepras
  • HY-17020A
    Miglustat hydrochloride
    5+ Cited Publications

    N-Butyldeoxynojirimycin hydrochloride; NB-DNJ hydrochloride; OGT 918 hydrochloride

    Glucosylceramide Synthase (GCS) Neurological Disease Inflammation/Immunology
    Miglustat (N-Butyldeoxynojirimycin) hydrochloride is an orally active and reversible ceramide glucosyltransferase inhibitor, with blood-brain barrier permeability. Miglustat hydrochloride can be used for the research of type I gaucher disease .
    Miglustat hydrochloride
  • HY-124476
    Cystamine
    5 Publications Verification

    Caspase Glutaminase Apoptosis Cancer
    Cystamine is the disulfide form of the free thiol, cysteamine. Cystamine is an orally active transglutaminase (Tgase) inhibitor. Cystamine also has inhibition activity for caspase-3 with an IC50 value of 23.6 μM. Cystamine can be used for the research of severals diseases including Huntington's disease (HD) .
    Cystamine
  • HY-B0203
    Nebivolol
    3 Publications Verification

    R 065824

    Adrenergic Receptor Cardiovascular Disease Endocrinology Cancer
    Nebivolol (R 065824) is an orally active beta receptor blocker and has the high beta(1)-receptor affinity. Nebivolol has direct vasodilator properties and adrenergic blocking characteristics. Nebivolol can be used for the research of kinds of diseases such as hypertension, coronary artery disease, congestive heart failure and ischemic heart disease .
    Nebivolol
  • HY-12947
    GNE-3511
    5+ Cited Publications

    MAP3K Neurological Disease
    GNE-3511 is an orally active bioavailable and brain-penetrant dual leucine zipper kinase (DLK) inhibitor with a Ki of 0.5 nM. GNE-3511 can cross the blood-brain-barrier and can be used for the research of neurodegenerative diseases .
    GNE-3511
  • HY-N7560
    Safranal
    5+ Cited Publications

    Keap1-Nrf2 Neurological Disease Inflammation/Immunology
    Safranal is an orally active main component of Saffron (Crocus sativus) and is responsible for the unique aroma of this spice. Safranal has neuroprotective and anti-inflammatory effects and has the potential for Parkinson’s disease research .
    Safranal
  • HY-157646
    MZ-101
    2 Publications Verification

    GYS1-IN-2

    Glycosyltransferase Metabolic Disease
    MZ-101 (GYS1-IN-2) is an orally active, potent and selective small-molecule glycogen synthase 1 (GYS1) inhibitor with with an IC50 value of 0.041 µM. MZ-101 reduces glycogen concentrations in cells and in mice. MZ-101 can used to study GYS1 -mediated Pompe disease and other glycogen storage diseases .
    MZ-101
  • HY-15908
    BCA
    5+ Cited Publications

    Disodium bicinchoninate

    Beta-secretase Neurological Disease Cancer
    BCA (Disodium bicinchoninate) is an orally active and non-competitive Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor with an IC50 value of 28 µM, a Ki value of 43 µM. BCA shows anticancer activity. BCA has the potential for the research of Alzheimer's disease (AD) .
    BCA
  • HY-118284
    Vicagrel
    1 Publications Verification

    P2Y Receptor Cardiovascular Disease
    Vicagrel is a potent, safe and orally active antiplatelet agent, which works by irreversibly inhibiting P2Y12 receptor. Vicagrel can be used for the research of blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease .
    Vicagrel
  • HY-W020050
    Cystamine dihydrochloride
    5 Publications Verification

    Caspase Glutaminase Apoptosis Neurological Disease Cancer
    Cystamine (dihydrochloride) is the disulfide form of the free thiol, cysteamine. Cystamine is an orally active transglutaminase (Tgase) inhibitor. Cystamine also has inhibition activity for caspase-3 with an IC50 value of 23.6 μM. Cystamine can be used for the research of severals diseases including Huntington's disease (HD) .
    Cystamine dihydrochloride
  • HY-124729
    BL-918
    3 Publications Verification

    ULK Autophagy Neurological Disease
    BL-918 is an orally active UNC-51-like kinase 1 (ULK1) activator with an EC50 of 24.14 nM. BL-918 exerts its cytoprotective autophagic effect by targeting ULK complex. BL-918 has the potential for Parkinson’s disease (PD) treatment .
    BL-918
  • HY-15381
    Fingolimod phosphate
    1 Publications Verification

    FTY720 phosphate

    LPL Receptor Infection Neurological Disease Inflammation/Immunology
    Fingolimod phosphate (FTY720 phosphate) is an orally active sphingosine 1-phosphate (S1P) receptor agonist. Fingolimod phosphate can promote the neuroprotective effects of microglia. Fingolimod phosphate can be used for the research of multiple sclerosis and neurologic diseases .
    Fingolimod phosphate
  • HY-156963

    FP-025

    MMP Inflammation/Immunology
    Aderamastat (FP-025) is an orally active, selective MMP-12 inhibitor. Aderamastat provides protection against house dust mite (HDM)-sensitized allergic asthma. Aderamastat can be used in the research of respiratory diseases, including chronic inflammatory airway diseases and pulmonary fibrosis .
    Aderamastat
  • HY-16747

    SHP625 chloride; LUM001 chloride; Lopixibat chloride

    Apical Sodium-Dependent Bile Acid Transporter Metabolic Disease
    Maralixibat (SHP625) chloride is an orally active ileal bile acid transporter (IBAT) inhibitor. Maralixibat chloride can be used for the research of rare cholestatic liver diseases including Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC) and biliary atresia .
    Maralixibat chloride
  • HY-12282

    LRRK2 Neurological Disease
    GNE-9605 is a potent, orally active, selective Leucine-rich repeat kinase 2 (LRRK2) inhibitor with an IC50 value of 18.7 nM. GNE-9605 inhibits LRRK2 Ser1292 autophosphorylation. GNE-9605 can be used in research of Parkinson's disease (PD) .
    GNE-9605
  • HY-108411
    Emedastine
    1 Publications Verification

    Histamine Receptor Inflammation/Immunology
    Emedastine is an orally active, selective and high affinity histamine H1 receptor antagonist with a Ki value of 1.3 nM. Emedastine is a benzimidazole derivative with potent antiallergic properties and used for allergic rhinitis, allergic skin diseases and allergic conjunctivitis .
    Emedastine
  • HY-P3499

    Guanylate Cyclase Inflammation/Immunology
    Dolcanatide is an orally active GC-C (guanylate cyclase-C) agonist. Dolcanatide shows laxative, anti-nociceptive and anti-inflammatory activity. Dolcanatide can be used in inflammatory bowel disease research .
    Dolcanatide
  • HY-B1804

    Trioctanoin; Glyceryl trioctanoate

    Endogenous Metabolite Neurological Disease Inflammation/Immunology
    Tricaprilin (Trioctanoin) is an orally active and well tolerated ketogenic agent that safely induces ketosis. Tricaprilin restores brain electrical activity and metabolism to help counteract neuroinflammation in migraine. Tricaprilin is promising for research of migraine prevention and Alzheimer’s disease (AD). Tricaprilin is a pure C8 medium chain triglyceride (MCT) .
    Tricaprilin
  • HY-16743A
    Ibiglustat (L-Malic acid)
    3 Publications Verification

    Venglustat (L-Malic acid); SAR402671 (L-Malic acid); GZ402671 (L-Malic acid)

    Glucosylceramide Synthase (GCS) Metabolic Disease
    Ibiglustat (Venglustat) L-Malic acid is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat L-Malic acid can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease .
    Ibiglustat (L-Malic acid)
  • HY-128442

    Phenyl hydrogen sulfate

    Endogenous Metabolite Metabolic Disease
    Phenyl sulfate is an orally active gut microbiota-derived metabolite. Phenyl sulfate induces albuminuria and podocyte damage in experimental models of diabetes. Phenyl sulfate can be used as a disease marker in diabetic kidney disease .
    Phenyl sulfate
  • HY-101918

    Thrombin Cardiovascular Disease
    DS-1040 Tosylate is an orally active, selective inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) with IC50s of 5.92 nM and 8.01 nM for human and rat TAFIa. DS-1040 Tosylate is a fibrinolysis enhancer for thromboembolic diseases .
    DS-1040 Tosylate
  • HY-116565
    Usmarapride
    1 Publications Verification

    SUVN-D4010

    5-HT Receptor Neurological Disease
    Usmarapride (SUVN-D4010) (Example 3)is a potent, selective, orally active and brain penetrant 5-HT4 receptor partial agonist (EC50=27.5 nM). Usmarapride (SUVN-D4010) can be used for the research of cognitive deficits associated with Alzheimer's disease .
    Usmarapride
  • HY-124344

    Interleukin Related Neurological Disease
    Avenanthramide C is an orally active avenanthramide that can be isolated from oat seeds. Avenanthramide C decreases the protein expression of cleaved caspase-3 and increases the expression of p-GSK3β(Ser9) and IL-10 levels. Avenanthramide C has the potential for the research of Alzheimer’s disease .
    Avenanthramide C
  • HY-15178

    GRC 3886

    Phosphodiesterase (PDE) Inflammation/Immunology
    Oglemilast (GRC 3886) is a potent and orally active phosphodiesterase-4 (PDE4) inhibitor with an IC50 of 0.5 nM for PDE4D3. Oglemilast inhibits pulmonary cell infiltration, including eosinophilia and neutrophilia in vitro and in vivo. Oglemilast has the potential for inflammatory airway diseases .
    Oglemilast
  • HY-B0731A

    SM-9018 free base

    5-HT Receptor Dopamine Receptor Neurological Disease
    Perospirone (SM-9018 free base) is an orally active antagonist of 5-HT2A receptor (Ki=0.6 nM) and dopamine D2 receptor (Ki=1.4 nM), and also a partial agonist of 5-HT1A receptor (Ki=2.9 nM). Perospirone is an atypical antipsychotic agent and has the potential for schizophrenic disease research .
    Perospirone
  • HY-125558

    ORG-34517

    Glucocorticoid Receptor Neurological Disease
    PT150 (ORG-34517) is a competitive and orally active glucocorticoid receptor antagonist. PT150 shows neuroprotective effects. PT150 has the potential for the research of Parkinson’s disease .
    PT150
  • HY-144619

    Toll-like Receptor (TLR) Inflammation/Immunology
    TLR7/8 antagonist 2 (Compound 15) is a potent and orally active agonist of TLR7/8 with IC50s of 4.9 and 0.6 nM, respectively. Inappropriate activation of TLR7 and TLR8 is linked to several autoimmune diseases, such as lupus erythematosus. TLR7/8 antagonist 2 has the potential for the research of autoimmune diseases .
    TLR7/8 antagonist 2
  • HY-A0027

    Histamine Receptor Phosphodiesterase (PDE) Inflammation/Immunology Endocrinology
    Fenspiride, an orally active non-steroidal antiinflammatory agent, is an antagonist of H1-histamine receptor. Fenspiride inhibites phosphodiesterase 3 (PDE3), phosphodiesterase 4 (PDE4) and phosphodiesterase 5 (PDE5) activities with -log IC50 values of 3.44, 4.16 and approximately 3.8, respectively. Fenspiride can be used for the research of respiratory diseases .
    Fenspiride hydrochloride
  • HY-16743B
    Ibiglustat succinate
    3 Publications Verification

    Venglustat succinate; SAR402671 succinate; GZ402671 succinate

    Glucosylceramide Synthase (GCS) Neurological Disease
    Ibiglustat (Venglustat) succinate is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat succinate can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease .
    Ibiglustat succinate
  • HY-138453

    LPA1 receptor antagonist 2

    LPL Receptor Inflammation/Immunology
    ACT-1016-0707 (Compound 49) is an orally active and selective LPA1 receptor antagonist. ACT-1016-0707 can be used for the research of fibrotic diseases .
    ACT-1016-0707
  • HY-162076

    Cathepsin Neurological Disease
    AEP-IN-3 (compound 18) is an orally active, potent and brain penetrant asparagine endopeptidase (AEP) inhibitor, with an IC50 of 7.8 ± 0.9 nM. AEP-IN-3 can be used for Alzheimer’s Disease (AD) research .
    AEP-IN-3
  • HY-145721A

    GED-0301 sodium

    TGF-beta/Smad Inflammation/Immunology
    Mongersen sodium is a specific and orally active SMAD7 antisense oligonucleotide. Mongersen sodium restores TGF-β1 activity leading to inhibition of inflammatory signals. Mongersen sodium can attenuate Crohn's disease-like experimental colitis in mice .
    Mongersen sodium
  • HY-145721

    GED-0301

    TGF-beta/Smad Inflammation/Immunology
    Mongersen (GED-0301) is a specific and orally active SMAD7 antisense oligonucleotide. Mongersen restores TGF-β1 activity leading to inhibition of inflammatory signals. Mongersen can attenuate Crohn's disease-like experimental colitis in mice .
    Mongersen
  • HY-144266

    Glucosylceramide synthase-IN-1

    Glucosylceramide Synthase (GCS) Neurological Disease Metabolic Disease
    Glucosylceramide synthase-IN-1 (T-036), a chemical probe, a potent, brain-penetrant and orally active glucosylceramide synthase (GCS) inhibitor with IC50s of 31 nM and 51 nM for human GCS and mouse GCS, respectively. Glucosylceramide synthase-IN-1 can be used for Gaucher's disease research .
    TP-060
  • HY-161735

    CXCR Inflammation/Immunology
    CXCR4-IN-3 (compound XVI) is an orally active and potent inhibitor targeting the inflammation-related receptor CXCR4, with an IC50 of 3.2 nM. CXCR4-IN-3 exhibits potent antichemotactic activity, at 79.19±2.33% inhibition. CXCR4-IN-3 shows anti-inflammatory activity. CXCR4-IN-3 can be used for IBD (inflammatory bowel disease) research .
    CXCR4-IN-3
  • HY-105003

    Adenosine Receptor Neurological Disease
    ST 1535 is a potent and orally active A2A adenosine receptor antagonist. ST 1535 shows antiparkinsonian activity and antitremorigenic effects. ST 1535 has the potential for the research of Parkinson’s disease .
    ST 1535
  • HY-16748

    ABT-126

    nAChR Neurological Disease
    Nelonicline (ABT-126) is an orally active and selective α7 nicotinic receptor agonist with high affinity to α7 nAChRs in human brain (Ki=12.3 nM). Nelonicline is used for the research of shizophrenia and Alzheimer's disease .
    Nelonicline
  • HY-N7560R

    Keap1-Nrf2 Reference Standards Neurological Disease Inflammation/Immunology
    Safranal (Standard) is an analytical standard for Safranal. This product is intended for research and analytical applications. Safranal is the main component of saffron (Crocus sativus), is orally active, and is the source of the spice's unique aroma. Safranal has neuroprotective and anti-inflammatory effects and has research potential for Parkinson's disease.
    Safranal (Standard)
  • HY-111313

    Cholecystokinin Receptor Metabolic Disease
    JNJ-26070109 is a high-affinity, competitive, orally bioactive, and selective cholecystokinin 2 (CCK2) receptor antagonist with good pharmacokinetic properties, with pKis of 8.49, 7.99, and 7.70 for human, rat, and dog CCK2 receptors, respectively. The dual function of CCK2 receptors in regulating gastric acid secretion and growth of the gastrointestinal mucosa make this an attractive and novel target for the research of gastroesophageal reflux disease .
    JNJ-26070109
  • HY-19490A

    (S)-AQW-051

    nAChR Neurological Disease
    (S)-VQW-765 ((S)-AQW-051) is an orally active, selective and effective α7 nicotinic ACh receptor (nAChR) partial agonist. (S)-VQW-765 has potential applications in cognitive disorders related to neurological diseases, such as Alzheimer's disease or schizophrenia .
    (S)-VQW-765

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: